BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

...register it www.biocenturychinasummit.com. Coming out of this we ran a survey on the outlook for China biopharma...
...by the responses in the biotechs, who we asked to say what they think the China biopharma...
BioCentury | Sep 19, 2020
Politics, Policy & Law

Biopharma companies, investors scrambling to work around WeChat ban

...never get to people.” Loncar created the Loncar China BioPharma...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Jones Industrial Average (DJIA) 1% 15% S&P 500 1% 19% NASDAQ Composite 0% 21% Loncar China BioPharma...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...iShares NASDAQ Biotechnology ETF (IBB) -2% 13% SPDR S&P Biotech ETF (XBI) -3% 22% Loncar China BioPharma...
BioCentury | May 24, 2019
Company News

CFIUS influence may have prompted Momenta's restructuring

...political climate associated with international investment in U.S. business." Last month, reports emerged that another U.S.-China biopharma...
BioCentury | May 14, 2019
Financial News

Trade tensions sink biotech shares as markets skid

...Average, Standard & Poor’s 500 index and the NASDAQ Composite were off 2-3%. The Loncar China BioPharma...
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...“Table: Index Performance”). Table: Index performance Index 1Q19 SPDR S&P Biotech ETF (XBI) 26% Loncar China BioPharma...
BioCentury | Jan 18, 2019
Politics & Policy

Winners of China's centralized procurement to secure over 60% market share

...Wu said that national roll out of the program will likely bring volatility to the China biopharma...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...DRG) -4% 4% Dow Jones Industrial Average (DJIA) -12% -6% S&P 500 -14% -6% Loncar China BioPharma...
BioCentury | Jan 11, 2019
Company News

Regulatory reforms in China spark Samsung Bioepis deal with 3SBio

...The regulatory reforms and growing China biopharma market has led South Korean company Samsung Bioepis Co. Ltd...
Items per page:
1 - 10 of 40
BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

...register it www.biocenturychinasummit.com. Coming out of this we ran a survey on the outlook for China biopharma...
...by the responses in the biotechs, who we asked to say what they think the China biopharma...
BioCentury | Sep 19, 2020
Politics, Policy & Law

Biopharma companies, investors scrambling to work around WeChat ban

...never get to people.” Loncar created the Loncar China BioPharma...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Jones Industrial Average (DJIA) 1% 15% S&P 500 1% 19% NASDAQ Composite 0% 21% Loncar China BioPharma...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...iShares NASDAQ Biotechnology ETF (IBB) -2% 13% SPDR S&P Biotech ETF (XBI) -3% 22% Loncar China BioPharma...
BioCentury | May 24, 2019
Company News

CFIUS influence may have prompted Momenta's restructuring

...political climate associated with international investment in U.S. business." Last month, reports emerged that another U.S.-China biopharma...
BioCentury | May 14, 2019
Financial News

Trade tensions sink biotech shares as markets skid

...Average, Standard & Poor’s 500 index and the NASDAQ Composite were off 2-3%. The Loncar China BioPharma...
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...“Table: Index Performance”). Table: Index performance Index 1Q19 SPDR S&P Biotech ETF (XBI) 26% Loncar China BioPharma...
BioCentury | Jan 18, 2019
Politics & Policy

Winners of China's centralized procurement to secure over 60% market share

...Wu said that national roll out of the program will likely bring volatility to the China biopharma...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...DRG) -4% 4% Dow Jones Industrial Average (DJIA) -12% -6% S&P 500 -14% -6% Loncar China BioPharma...
BioCentury | Jan 11, 2019
Company News

Regulatory reforms in China spark Samsung Bioepis deal with 3SBio

...The regulatory reforms and growing China biopharma market has led South Korean company Samsung Bioepis Co. Ltd...
Items per page:
1 - 10 of 40